ストックスクリーナーアプリを入手
0.00
100.00%
-1.71
前日終値:
$1.71
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$10.59M
収益：
-
当期純損益:
$-35.80M
株価収益率:
0.00
EPS:
-2.97
ネットキャッシュフロー:
$-37.18M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$27.78
Aptose Biosciences Inc Stock (APTO) Company Profile
名前
Aptose Biosciences Inc
セクター
電話
310-849-8060
住所
66 WELLINGTON STREET WEST, SUITE 5300, TORONTO, ON
APTO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
APTO
Aptose Biosciences Inc
|
0.00 | 10.59M | 0 | -35.80M | -37.18M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.40 | 114.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
535.74 | 55.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
306.39 | 39.64B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
569.83 | 35.64B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
266.21 | 28.55B | 3.81B | -644.79M | -669.77M | -6.24 |
Aptose Biosciences Inc Stock (APTO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-10-19 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-09-22 | 開始されました | Alliance Global Partners | Buy |
| 2020-02-20 | 開始されました | Maxim Group | Buy |
| 2020-02-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-01-09 | 開始されました | Piper Sandler | Overweight |
| 2019-03-01 | 開始されました | RBC Capital Mkts | Outperform |
| 2018-11-16 | 開始されました | B. Riley FBR | Buy |
| 2017-12-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-10-23 | 再開されました | ROTH Capital | Buy |
| 2017-09-07 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2017-06-08 | 開始されました | Rodman & Renshaw | Neutral |
すべてを表示
Aptose Biosciences Inc (APTO) 最新ニュース
(APS) Investment Analysis and Advice (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences Reports Promising Results from TUSCANY Trial in AML - MSN
Aptose Presents Safety, Response, and MRD Clinical Data from TUS - GuruFocus
Aptose reports promising data from TUS+VEN+AZA therapy for AML By Investing.com - Investing.com South Africa
Aptose reports promising data from TUS+VEN+AZA therapy for AML - Investing.com Canada
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress - The Manila Times
APTOAptose Announces Reverse Share Split - Revista ADVFN
Where are the Opportunities in (APS) (APS:CA) - news.stocktradersdaily.com
(APS) Financial Trading Report (APS:CA) - news.stocktradersdaily.com
(APS) Technical Pivots with Risk Controls (APS:CA) - news.stocktradersdaily.com
Aptose's Closing of US$3M Investment by Hanmi Pharmaceutical - McCarthy Tétrault
Aptose Biosciences completes Public Offering of Common Shares for US$74.2M - McCarthy Tétrault
Aptose Biosciences Inc. enters into exclusive license agreement with Hanmi Pharmaceutical - McCarthy Tétrault
Aptose Biosciences Inc. Completes US$4.43M Registered Direct Offering and Concurrent Private Placement - McCarthy Tétrault
Aptose Biosciences Inc. announces it entered into a $25M Committed Equity Facility - McCarthy Tétrault
Aptose enters equity distribution agreement with Piper Sandler and Canaccord Genuity - McCarthy Tétrault
Aptose Announces Results from Annual and Special Meeting of Shar - GuruFocus
Aptose Announces Results from Annual and Special Meeting of Shareholders - The Globe and Mail
Analyzing Monte Rosa Therapeutics (NASDAQ:GLUE) and Aptose Biosciences (NASDAQ:APTO) - Defense World
Trading (APS) With Integrated Risk Controls (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences (NASDAQ:APTO) Now Covered by Analysts at StockNews.com - Defense World
(APS) Investment Performance Report (APS:CA) - news.stocktradersdaily.com
Stocks In Play: Aptose Biosciences Inc. By Baystreet.ca - Investing.com Canada
Stocks In Play: Aptose Biosciences Inc. - Barchart.com
Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee | APTOF Stock N - GuruFocus
Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee - The Manila Times
(APS) Advanced Equity Analysis (APS:CA) - news.stocktradersdaily.com
Aptose Selected for Prestigious Oral Presentation of Data from T - GuruFocus
Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress - St. Catharines Standard
StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO) - Defense World
Aptose Biosciences Reports Q1 2025 Financial Results - TipRanks
(APS) On The My Stocks Page (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences: Q1 Earnings Snapshot - CT Insider
Aptose Biosciences Reports Promising AML Trial Results and Expands Market Presence - TipRanks
Aptose Biosciences Inc. SEC 10-Q Report - TradingView
Aptose Reports First Quarter 2025 Results - The Manila Times
(APS) Market Performance Analysis (APS:CA) - news.stocktradersdaily.com
In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML - insights.citeline.com
Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com - Defense World
(APS) Technical Patterns and Signals (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences Inc. - Baystreet.ca
Aptose Biosciences Reports Promising Results from TUSCANY Trial for AML Treatment - TipRanks
Aptose Provides Clinical Update for Tuspetinib-based Triple Drug Therapy in Tuscany Trial - marketscreener.com
Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial - The Manila Times
Breakthrough AML Treatment: Triple Drug Therapy Shows Complete Remission in Patients with Resistant Mutations - Stock Titan
Aptose Biosciences, Inc. to Host Earnings Call - ACCESS Newswire
Comparing Sana Biotechnology (NASDAQ:SANA) & Aptose Biosciences (NASDAQ:APTO) - Defense World
Aptose Biosciences Inc (APTO) 財務データ
収益
当期純利益
現金流量
EPS
2.97%
0.52%
大文字化:
|
ボリューム (24 時間):